KAND-567 is under clinical development by Kancera and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KAND-567’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KAND-567 (AZD-8797) is under development for the treatment of acute cardiovascular inflammation caused during and after treatment for myocardial infarction, acute respiratory distress syndrome in coronavirus disease 2019 (COVID-19) infection, myocardial infraction (heart attack), ovarian cancer, epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer. It is administered orally and intravenously. The drug candidate targets fractalkine receptor (CX3C Chemokine Receptor 1). It was also under development for the treatment of spinal cord injury, multiple sclerosis, cancer pain, pancreatic cancer and cardiovascular inflammation.
Kancera is a developer of drug candidates for the treatment of cancer. The company’s pipeline products include fractalkine inhibitor AZD8797, used to stop tumor growth; small molecule HDAC6 inhibitors, for neutralizing blood cancer; small molecule PFKFB3 inhibitors, for stopping energy supply from glucose to solid tumors; small molecule ROR inhibitors, for to reprogram cancer cells to destroy themselves, and small molecule inhibitors of epigenetic processes in parasites for developing new treatments to malaria schistosomiasis and FRACTALKINE-ANTAGONISTS: a new treatment for inflammation and cardiac protection. It caters to pharmaceutical and biotechnology companies. The company operates through its facility located in Stockholm, Sweden. Kancera is headquartered in Stockholm, Sweden.
For a complete picture of KAND-567’s drug-specific PTSR and LoA scores, buy the report here.